Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03858322 · ClinicalTrials.gov registry record · Phase 1
'ADVANCE' (A Pilot Trial)
A Phase 1 study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 5
- Study locations
NCT03858322 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 41 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT03858322, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is being conducted to carefully study how chemotherapy is tolerated in group of patients age 70.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Carboplatin
- DRUG Paclitaxel
Study Locations (5)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) at Milford Regional Medical Center - Milford
- Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in Clinical Affiliation with South Shore Hospital - South Weymouth
California
- City of Hope National Medical Center - Duarte
North Carolina
- Novant Health Oncology Specialists - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-03-21 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03858322
The ClinicalTrials.gov registry entry for NCT03858322 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT03858322 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03858322 about?
NCT03858322 is a clinical study titled "'ADVANCE' (A Pilot Trial)". This study is being conducted to carefully study how chemotherapy is tolerated in group of patients age 70.
What is the current status of trial NCT03858322?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2019-03-21. Estimated completion is 2026-06-30.
What conditions does trial NCT03858322 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03858322?
The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03858322?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03858322 being conducted?
This trial has 5 study locations across California, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.